Accessibility Statement

Press Releases


Lilly Declares Second-Quarter 2024 Dividend

May 6, 2024

Tags |  Financial

INDIANAPOLIS , May 6, 2024   /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on June 10, 2024, to shareholders of record at the close of




Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum

April 30, 2024

Tags |  Financial

Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn's disease in the U.S.




Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement

April 16, 2024

Tags |  Financial

INDIANAPOLIS , April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial




Lilly to Participate in Cowen's 44th Annual Health Care Conference

February 20, 2024

Tags |  Financial

INDIANAPOLIS , Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024 . Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time .




Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

February 6, 2024

Tags |  Financial

Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included  FDA approval of Zepbound for




Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

January 23, 2024

Tags |  Financial

INDIANAPOLIS , Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the




Lilly to Participate in J.P. Morgan Healthcare Conference

January 2, 2024

Tags |  Financial

INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference , Jan. 8-11, 2024 . David A. Ricks, Lilly 's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time .




Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend

December 8, 2023

Tags |  Financial

INDIANAPOLIS , Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock.




Lilly to Participate in Evercore ISI HealthCONx Conference

November 14, 2023

Tags |  Financial

INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023 . Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research




Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity

November 2, 2023

Tags |  Financial

Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue in Q3 2023 increased 24%.